Is This Stock a Screaming Buy: CytomX Therapeutics, Inc. (NASDAQ:CTMX)

Equity Research firms currently have a positive stance on shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX). The majority of analysts covering the equity have a consensus Strong Buy recommendation on the stock, yielding a score of 1.30. This is based on the research brokerage reports taken into consideration by Thomson Reuters. Those same analysts are projecting that the stock will reach $20.00 on a short term basis.

At the time of writing, the stock was trading at $15.37. This represents a change from the opening price of -0.58%. In terms of performance, year to date, the stock is -26.40%. The monthly stock performance comes in at 20.57%. For the quarter, shares are performing at 43.42%. Weekly performance analysis shows the equity at -1.09%.

In taking a look at technical levels, shares are trading 18.55% away from the 50 day simple moving average and 19.90% away from the 200 day simple moving average. Based on a recent bid, the stock is trading -37.72% away from it’s 52- week high and 70.59% away from its 52 week low. After the recent moves, investors may also look to see if the stock has entered oversold or overbought territory and could be ripe for a bounce. As of writing, CytomX Therapeutics, Inc.’s RSI stands at 56.12. In looking at volatility levels, the shares saw weekly volatility of 5.22% and 7.14% over the past month.

Leave a Comment